Cardiac Changes in Myeloproliferative Neoplasms

Status Not yet recruiting

Clinical Trial Summary

Myeloproliferative neoplasms are heterogeneous group of clonal hematopoietic stem cell neoplasms with excessive proliferation of one or more of the erythroid, megakaryocytic, or myeloid lineages and relatively normal maturation resulting in increased numbers of red cells, platelets, and/or granulocytes in the peripheral blood. Constitutive tyrosine kinase activation appears to be a common pathogenetic mechanism.

Clinical Trial Description

According to worldwide study of prevalence of myeloproliferative neoplasms revealed:

Incidence of polycythemia vera ranged 0.01 to 2.61 per 100.000 population and the prevalence ranging from 0.49 to 46.88 per 100.000 population. Incidence of essential thrombocythemia is 0.21 to 2.27 per 100.000 population, prevalence ranging between 11.00 - 42.51 per 100.000 population.

Primary myelofibrosis incidence is 1.15 -4.99 per 100.000 population and prevalence ranging between 1.76 - 4.05 per 100.000 population.In previous studies, cardiac involvement including coronary arterial thrombosis, myocardial infarction, pulmonary hypertension, asymptomatic pericardial effusion, cardiac tamponade, intractable cardiac failure due to intraventricular stenosis and valvular stenosis that occur in myeloproliferative neoplasms. There is a few number of studies in which cardiac lesions were evaluated in myeloproliferative neoplasms by using transthoracic echocardiography but still inadequate, so we need to understand more about cardiovascular complications in myeloproliferative neoplasms. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03177928
Study type	Interventional
Source	Assiut University
Contact	Osama A Ibrahim, Proffessor.
Phone	00201006372498
Email	oibrahiem@yahoo.com
Status	Not yet recruiting
Phase	N/A
Start date	September 1, 2017
Completion date	February 28, 2019

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04022785` - PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome	Phase 1
Not yet recruiting	`NCT05440838` - Identification of Factors Associated With Treatment Response in Patients With Polycythemia Vera, Essential Thrombocythemia, and Pre-myelofibrosis.
Completed	`NCT03941769` - 2018-0674 - IL-7 for T-Cell Recovery Post Haplo and CB Transplant - Phase I/II	Phase 1/Phase 2
Completed	`NCT04666025` - SARS-CoV-2 Donor-Recipient Immunity Transfer
Terminated	`NCT02877082` - Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients	Phase 2
Recruiting	`NCT03589729` - Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers	Phase 2
Completed	`NCT04605211` - A Distress Reduction Intervention for Patients With BCR-ABL-Negative MPNs or CML on Tyrosine Kinase Inhibitors	N/A
Active, not recruiting	`NCT03588078` - Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine	Phase 1/Phase 2
Recruiting	`NCT05521204` - Olverembatinib for FGFR1-rearranged Neoplasms	Phase 2
Enrolling by invitation	`NCT04994158` - MASCOT Registry of Patients With Myeloproliferative Neoplasms Associated Splanchnic Vein Thrombosis
Completed	`NCT04192916` - Use of Direct Oral Anticoagulants (DOACs) in Patients With Ph-negative Myeloproliferative Neoplasms
Recruiting	`NCT05419648` - Role of Monocytes Sub-populations in Thrombosis Associated With Myeloproliferative Neoplasms (MonSThr)
Recruiting	`NCT04955938` - A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms	Phase 1
Recruiting	`NCT04942080` - Interest of CALR Allele Burden in Diagnosis and Follow-up of Patients With CALR Mutated Myeloproliferative Syndromes (CALRSUIVI)	N/A
Completed	`NCT04146038` - Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease	Phase 2
Not yet recruiting	`NCT06468033` - P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk	Phase 3
Completed	`NCT02862366` - Role of the Circulating Procoagulants Microparticles in the Hypercoagulability of MNP Ph1-
Not yet recruiting	`NCT06022341` - MultiOmic characteriZation of Acute Myeloid Leukemia Evolving From myelopRoliferative Neoplasm to Identify New Targeted Therapeutic Strategies	N/A
Recruiting	`NCT03630991` - Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy	Phase 1
Not yet recruiting	`NCT04527666` - Anticoagulation in Gastroesophageal Varices and JAK2 Mutation